ZARVY

Foracort 400 Rotacaps is a combination dry powder inhaler (DPI) that delivers Formoterol Fumarate (6mcg) and Budesonide (400mcg), designed for long-term management of asthma and chronic obstructive pulmonary disease (COPD). This inhaler provides dual-action relief, helping to relax the airway muscles and reduce inflammation, ensuring better lung function and symptom control. Formoterol is a long-acting beta-2 adrenergic agonist (LABA) that works by relaxing the bronchial muscles, allowing smoother airflow for up to 12 hours. Budesonide, an inhaled corticosteroid (ICS), helps reduce airway inflammation and prevents asthma flare-ups. This combination is particularly effective for patients experiencing persistent asthma symptoms or frequent COPD exacerbations. Foracort 400 Rotacaps is designed for use with a Rotahaler, a dry powder inhalation device that allows the deep lung delivery of medication without the need for propellants. Unlike rescue inhalers, this medication is not for immediate symptom relief but is meant for consistent, long-term control of respiratory conditions.

Formonide 400 Inhaler is a combination metered-dose inhaler (MDI) containing Formoterol Fumarate (6mcg) and Budesonide (400mcg), designed for long-term asthma and COPD (chronic obstructive pulmonary disease) management. This inhaler is a dual-action therapy that provides both bronchodilation and anti-inflammatory effects, improving lung function and preventing respiratory symptoms. Formoterol, a long-acting beta-2 agonist (LABA), works by relaxing airway muscles, allowing better airflow and preventing sudden bronchospasms. Budesonide, an inhaled corticosteroid (ICS), reduces inflammation and mucus production, preventing frequent asthma attacks and COPD exacerbations. As an MDI, Formonide 400 ensures controlled and accurate medication delivery with each dose, making it ideal for daily maintenance therapy. However, it is not a rescue inhaler and should not be used to treat acute breathing difficulties.

Formost 400 Respicaps is a combination inhalation therapy designed for the long-term management of asthma and chronic obstructive pulmonary disease (COPD). It contains Formoterol Fumarate (6mcg), a long-acting bronchodilator (LABA), and Budesonide (400mcg), a potent inhaled corticosteroid (ICS). This combination helps to relax airway muscles, reduce inflammation, and prevent respiratory distress, making it an essential controller medication for chronic lung conditions. Formoterol acts as a bronchodilator, working for up to 12 hours to keep the airways open and reduce symptoms like wheezing, shortness of breath, and tightness in the chest. Budesonide, a glucocorticoid steroid, helps suppress airway inflammation, minimizing the risk of asthma exacerbations and COPD progression. Formost 400 Respicaps is designed for use with a Dry Powder Inhaler (DPI), ensuring effective medication delivery without the need for propellants. This makes it easier to inhale, particularly for patients with weak respiratory function. It is a preventative treatment and should not be used as a rescue inhaler for sudden breathing difficulties.

Foracort Forte Rotacaps is a combination inhalation therapy formulated with Formoterol Fumarate (12mcg) and Budesonide (400mcg), specifically designed for the long-term management of asthma and chronic obstructive pulmonary disease (COPD). This dry powder inhaler (DPI) delivers dual-action relief, effectively controlling bronchospasms and airway inflammation. Formoterol is a long-acting beta-2 adrenergic agonist (LABA) that works as a bronchodilator, relaxing the airway muscles and improving airflow for up to 12 hours. Budesonide, a corticosteroid, reduces inflammation in the airways, helping to prevent asthma attacks and COPD exacerbations. The combination of these two ingredients enhances respiratory function and ensures long-term symptom control. Foracort Forte Rotacaps is ideal for patients with moderate to severe asthma and COPD, offering a higher corticosteroid dosage (400mcg of Budesonide) to improve lung function, minimize exacerbations, and reduce hospital visits. As a controller medication, it is not for immediate relief but plays a crucial role in the daily maintenance of respiratory health.

Onbrez 150 Breezhaler is an original prescription inhalation therapy developed by Novartis, containing Indacaterol 150mcg, a once-daily ultra-long-acting beta-2 agonist (LABA). It is formulated for the maintenance treatment of chronic obstructive pulmonary disease (COPD), offering rapid and sustained bronchodilation that lasts up to 24 hours. Each dose is delivered via a capsule-based Breezhaler® device, ensuring effective and accurate administration of the medication.

Indamet 320 Rotacaps is a high-dose generic version of Onbrez, containing Indacaterol 320mcg, a once-daily ultra-long-acting beta-2 agonist (LABA) used for the maintenance treatment of moderate to severe chronic obstructive pulmonary disease (COPD). Manufactured by Glenmark, this rotacap formulation delivers 24-hour bronchodilation through a compatible dry powder inhaler (rotahaler), helping patients maintain improved airflow and symptom control throughout the day.

Loftair Inhaler 110/50 mcg is a generic inhalation therapy that combines Indacaterol 110 mcg and Glycopyrronium 50 mcg per capsule, designed for the long-term maintenance treatment of chronic obstructive pulmonary disease (COPD). This dual-action inhaler leverages the complementary mechanisms of a long-acting beta-2 agonist (LABA) and a long-acting muscarinic antagonist (LAMA) to enhance bronchodilation, thereby improving airflow and reducing respiratory symptoms in individuals with COPD. :contentReference[oaicite:0]{index=0}

Forglyn Plus Inhaler is a triple-action metered dose inhaler (MDI) formulated with Budesonide (160mcg), Formoterol Fumarate (4.8mcg), and Glycopyrrolate (9mcg), specifically designed for the management of chronic obstructive pulmonary disease (COPD) and severe asthma. This inhaler delivers anti-inflammatory, bronchodilatory, and anticholinergic effects, providing long-term control of airway obstruction and inflammation. - Budesonide is a corticosteroid that reduces inflammation and swelling in the airways, preventing respiratory distress. - Formoterol Fumarate is a long-acting beta-2 adrenergic agonist (LABA) that acts as a bronchodilator, relaxing airway muscles and improving airflow for up to 12 hours. - Glycopyrrolate is a long-acting muscarinic antagonist (LAMA) that blocks acetylcholine receptors, reducing mucus production and preventing bronchoconstriction. Forglyn Plus Inhaler is recommended for patients suffering from chronic airway diseases such as COPD, emphysema, and severe asthma, ensuring better lung function, fewer exacerbations, and improved breathing efficiency.

Nistami Inhaler 110/50 mcg is a generic dry powder inhalation therapy that combines Indacaterol 110mcg and Glycopyrronium 50mcg, formulated to deliver dual bronchodilation for patients with chronic respiratory diseases. Indacaterol is a long-acting β2-adrenergic agonist (LABA), while Glycopyrronium functions as a long-acting muscarinic antagonist (LAMA). This combination synergistically enhances airway smooth muscle relaxation, significantly improving airflow in patients with Chronic Obstructive Pulmonary Disease (COPD) and moderate to severe asthma. As part of the Respiratory Diseases category, Nistami Inhaler is designed for once-daily use, offering sustained bronchodilation to manage Asthma / COPD, Chronic Bronchitis, and as supportive care in conditions with airway hyperresponsiveness, such as post-viral bronchoconstriction following influenza or tonsillitis. The inclusion of both Indacaterol and Glycopyrronium ensures superior symptom control, reducing the need for rescue medications and improving overall respiratory quality of life.

Glycoair Breezhaler 110/50 mcg is a generic inhalation capsule combining Indacaterol (110mcg) and Glycopyrronium (50mcg), designed to provide dual bronchodilation for individuals suffering from chronic obstructive pulmonary disease (COPD) and moderate to severe asthma. Indacaterol acts as a long-acting beta2-adrenergic agonist (LABA), promoting sustained bronchial muscle relaxation, while Glycopyrronium is a long-acting muscarinic antagonist (LAMA) that blocks acetylcholine-induced bronchoconstriction. Together, these two agents synergize to provide prolonged airway dilation, ease of breathing, and significant reduction in respiratory symptoms. This inhaler is particularly useful in patients experiencing bronchitis, asthma/COPD overlap, or post-viral airway reactivity. It may also offer secondary symptomatic relief in respiratory conditions such as post-influenza bronchospasm or lingering airway constriction after tonsillitis, even though it is not a direct antimicrobial agent. It belongs to the Respiratory Diseases category under the subcategories Asthma / COPD and Bronchitis.

Ipravent 250 Respirator Solution is a generic inhalation formulation containing Ipratropium 250mcg, a short-acting anticholinergic bronchodilator. It is widely used for symptomatic relief in asthma, chronic obstructive pulmonary disease (COPD), and chronic bronchitis, particularly when airway constriction and mucus hypersecretion are present. By blocking muscarinic receptors in the airway smooth muscle, Ipratropium inhibits parasympathetic-mediated bronchial contraction and reduces mucus production, resulting in easier breathing. This solution is administered via nebulization and is especially effective for patients who require rapid symptom relief, including during acute exacerbations of COPD or asthma. Additionally, Ipravent is beneficial in managing post-infectious bronchospasm following influenza or upper respiratory tract infections. It is also sometimes used off-label for allergic rhinitis, helping reduce nasal congestion and runny nose through its local anticholinergic effects.

Foratec Respules 15mcg is a long-acting bronchodilator containing Formoterol Fumarate 15mcg, which is used for the management of chronic respiratory conditions such as asthma and chronic obstructive pulmonary disease (COPD). It provides prolonged bronchodilation, ensuring relief from airway obstruction, wheezing, breathlessness, and bronchospasms. Formoterol Fumarate is a selective beta-2 adrenergic agonist that acts by relaxing the smooth muscles of the airways, allowing easier airflow to the lungs. It has a rapid onset of action combined with a long duration of effect, making it an essential controller medication for individuals with persistent asthma or COPD. Foratec Respules is designed for nebulization therapy, delivering the medication directly into the lungs for quick and effective symptom relief. This formulation is particularly beneficial for patients who have difficulty using inhalers or require a more controlled and consistent delivery method.

Forglyn Inhaler is a combination bronchodilator formulated with Formoterol Fumarate (4.8mcg) and Glycopyrrolate (9mcg), designed for long-term management of chronic obstructive pulmonary disease (COPD). This metered-dose inhaler (MDI) delivers a controlled dose of medication to open the airways, reduce bronchospasms, and improve breathing efficiency. Formoterol is a long-acting beta-2 agonist (LABA) that relaxes airway muscles, allowing for better airflow and prolonged bronchodilation. Glycopyrrolate is an anticholinergic bronchodilator, reducing airway mucus production and preventing bronchoconstriction. Together, these active ingredients enhance respiratory function, reduce exacerbations, and improve exercise tolerance in COPD patients. Forglyn Inhaler is intended for maintenance therapy in moderate to severe COPD and is not a rescue inhaler for immediate relief. It provides 24-hour symptom control, helping patients breathe more comfortably and reduce dependency on short-acting inhalers.

Airz-F Digihaler is a metered-dose inhaler (MDI) formulated with Formoterol Fumarate (4.8mcg) and Glycopyrrolate (9mcg), specifically designed for the long-term management of chronic obstructive pulmonary disease (COPD), including chronic bronchitis and emphysema. This inhaler provides dual-action relief by combining a long-acting beta-2 adrenergic agonist (LABA) with a long-acting muscarinic antagonist (LAMA) to improve lung function and enhance respiratory capacity. Formoterol acts as a bronchodilator, helping to relax airway muscles and allow smoother airflow, while Glycopyrrolate works by blocking muscarinic receptors, reducing airway resistance, and preventing mucus overproduction. Together, these components significantly enhance breathing efficiency, reduce COPD exacerbations, and minimize symptoms like wheezing, shortness of breath, and persistent coughing. This medication is intended for daily maintenance therapy and should not be used as a rescue inhaler for acute bronchospasms. Patients who require consistent symptom control and improved exercise tolerance benefit greatly from this combination therapy.

Glycohale FB Rotacaps is a triple-action inhalation therapy containing Budesonide (400mcg), Formoterol Fumarate (12mcg), and Glycopyrronium (25mcg), designed for advanced respiratory disease management. This dry powdered inhaler (DPI) is primarily used for chronic obstructive pulmonary disease (COPD) and severe asthma, offering bronchodilation, anti-inflammatory action, and prolonged airway relaxation. - Budesonide is a corticosteroid that reduces airway inflammation, preventing sudden asthma and COPD exacerbations. - Formoterol Fumarate is a long-acting beta-2 agonist (LABA) that relaxes airway muscles, ensuring long-term bronchodilation. - Glycopyrronium is a long-acting muscarinic antagonist (LAMA) that prevents bronchial constriction, ensuring persistent airway openness. By combining these three potent components, Glycohale FB Rotacaps enhances lung function, minimizes respiratory distress, and provides extended symptom control for patients requiring comprehensive pulmonary therapy.

Indamet-G is a generic inhalation therapy containing Indacaterol 150mcg, Glycopyrronium 50mcg, and Mometasone 160mcg, designed to provide comprehensive management for chronic respiratory conditions such as COPD and asthma. This fixed-dose triple combination offers a multi-mechanistic approach: Indacaterol is a long-acting β2-agonist (LABA) that relaxes bronchial smooth muscles for extended bronchodilation; Glycopyrronium is a long-acting muscarinic antagonist (LAMA) that reduces airway constriction by blocking cholinergic signals; Mometasone is an inhaled corticosteroid (ICS) that attenuates inflammation within the respiratory tract. Indamet-G is especially beneficial for patients with moderate to severe airflow limitation, frequent exacerbations, or those unresponsive to dual bronchodilator therapy. It significantly improves lung function, enhances exercise tolerance, and reduces daily symptom burden. This formulation also supports bronchial stability during post-infectious recovery from Flu (Influenza) or upper respiratory infections, contributing to faster normalization of breathing in susceptible patients.

Asthalin 100mcg Inhaler contains Salbutamol (Albuterol) 100mcg, a short-acting beta-2 agonist (SABA) bronchodilator that provides rapid relief from asthma symptoms, bronchospasms, and breathing difficulties. It is commonly used for asthma, chronic obstructive pulmonary disease (COPD), and exercise-induced bronchoconstriction (EIB). Asthalin works by relaxing airway muscles, allowing easier breathing within minutes.

Asthalin 200mcg Rotacaps contains Salbutamol 200mcg, a potent bronchodilator used to relieve and prevent symptoms of asthma, chronic obstructive pulmonary disease (COPD), and bronchospasms. It belongs to the beta-2 adrenergic agonist class, which works by relaxing the airway muscles, allowing easier breathing. This dry powder inhalation (DPI) formulation is designed for quick relief, making it particularly effective for acute asthma attacks, exercise-induced bronchospasms, and sudden breathing difficulties. Salbutamol is widely prescribed as a rescue inhaler medication, helping patients regain normal breathing within minutes. Regular use of Asthalin 200mcg Rotacaps can enhance lung function, reduce airway resistance, and improve overall respiratory health. However, it should be used as directed, as overuse may lead to reduced effectiveness and side effects.